Dear Editors,
In the paper of Casset et al. [1] , we have recently shown that commercially available extracts from the house dust mite Dermatophagoides pteronyssinus from different European manufacturers differed considerably regarding their amount of the major allergens, Der p 1 and Der p 2, and often lacked other important allergens (e.g. Der p 5, Der p 7, Der p 10 and Der p 21). Because of this, some extracts failed to diagnose certain house dust mite-allergic patients.
The two different batches of D. pteronyssinus extracts from Stallergènes used in this study showed a good batch-to-batch consistency, but contained only low levels of Der p 1 and Der p 2. The other tested mite allergens, Der p 5, Der p 7, Der p 10 and Der p 21, could not be detected in the two batches ( table 1 ) . As a consequence, the Stallergènes extract failed to diagnose 2 house dust mite-allergic patients [1] .
Moingeon et al. [2] present in their 'Letter to the Editor' the quality checks which are routinely performed to guarantee phar-The finished products from Stallergènes are tested for their allergenic activity in comparison to an in-house reference standard. This test ensures a good batch-tobatch consistency of the extracts which was also seen in our study (table 1) [1] . However, in-house reference standards are not suitable for a comparison of extracts from different companies and are the reason for the differences seen in skin prick tests between extracts from different manufacturers [1] .
In summary, the quality control steps performed by Stallergènes during the manufacture of house dust mite extracts for diagnosis and immunotherapy may ensure some degree of batch-to-batch consistency of their extracts but they do not ensure the presence of all important mite allergens in the extracts. As a consequence, the extracts may fail in diagnostic tests and give suboptimal results in clinical trials. An improvement of the situation can only be expected from the use of defined recombinant allergens. 
